Llyord Mwaniki Highlights East Africa’s Push Toward Comprehensive Haemophilia Support
Novo Nordisk Haemophilia Foundation, shared a post on LinkedIn:
“The NNHF is proud to see our partners from Kenya, Tanzania, Uganda, and Rwanda come together to advocate for stronger haemophilia care at the East Africa Legislative Assembly office.
Their united voice demonstrates the power of regional coalitions to amplify impact and accelerate change – thank you for driving this conversation forward!”
Quoting Llyord Mwaniki’s post:
“Representatives from the Kenya Haemophilia Association, the Haemophilia Society of Tanzania, the Haemophilia Foundation of Uganda, and the Rwanda Fraternity Against Haemophilia came together to present to the General Purpose Committee of East Africa Legislative Assembly (EALA). Their message was clear and powerful: we must do more to advance haemophilia care across East Africa.
As part of the Novo Nordisk Haemophilia Foundation, I was proud to stand alongside these passionate advocates as they highlighted the urgent need for access to treatment, diagnostics, and comprehensive care – and the critical role that the governments are playing in making this a reality.
The EALA General Purpose Committee together with Hon MUSANGABATWARE Clément reviewed the recommendations and drafted a motion to support regional legislation for improved haemophilia care. We’ll continue to support and follow this process closely, ensuring that the voices of those affected remain at the heart of the conversation.
This is advocacy in action. And it’s a reminder that regional coalition can truly transform lives.”
Stay updated with Hemostasis Today.
-
Feb 23, 2026, 15:32Cheng-Hock Toh: The Paradox of Hematology
-
Feb 23, 2026, 15:20Rabab Al Dawood: Moderating the Coagulation and Hemostasis Session at the ISLH 1st Joint Conference
-
Feb 23, 2026, 15:16Amira Khater: Key Updates on Pulmonary Embolism Management from AHA and ACC Guidelines
-
Feb 23, 2026, 14:45Stacey McGeown: Rare Disease Awareness Day at QUB Marks the Start of Rare Disease Month
-
Feb 23, 2026, 13:53Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 1
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline
-
Feb 23, 2026, 12:37Reza Shojaei: EU’s Critical Medicines Act and Plasma Resilience